Head-To-Head Contrast: Organogenesis (NASDAQ:ORGO) versus Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) and Organogenesis (NASDAQ:ORGO) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Earnings and Valuation

This table compares Incyte and Organogenesis”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14 billion	4.82	$1.29 billion	$1.88	64.73
Organogenesis	$564.17 million	0.22	$37.03 million	($1.22)	-0.79

Incyte has higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Incyte and Organogenesis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Incyte	6.71%	7.92%	6.12%
Organogenesis	-39.34%	-55.28%	-23.72%

Risk and Volatility

Incyte has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Organogenesis has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for Incyte and Organogenesis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	1	13	11	0	2.40
Organogenesis	1	2	0	0	1.67

Incyte currently has a consensus target price of $132.86, indicating a potential upside of 9.17%. Organogenesis has a consensus target price of $4.33, indicating a potential upside of 349.05%. Given Organogenesis’ higher possible upside, analysts clearly believe Organogenesis is more favorable than Incyte.

Insider & Institutional Ownership

97.0% of Incyte shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Incyte beats Organogenesis on 10 of the 13 factors compared between the two stocks.

About Incyte

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

About Organogenesis

Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures and commercializes products for advanced wound care and surgical and sports medicine. The company’s products are designed to support tissue repair and healing in a range of clinical settings. Its portfolio includes wound-care products such as Apligraf, a bioengineered skin substitute, and products made from or incorporating materials including placental tissue and purified collagen. Organogenesis also offers products for surgical and sports medicine applications.